Behav Pharmacol
August 1, 2017
Michael B. Gatch, Sean B. Dolan, Michael J. Forster
36 citations
Four novel synthetic hallucinogens (25B-NBOMe, 25C-NBOMe, 25I-NBOMe, and 5-MeO-DALT) were tested in rats and mice for their behavioral effects. 25B-NBOMe, 25C-NBOMe, and 25I-NBOMe reduced locomotor activity in mice, while 5-MeO-DALT increased activity at 10 mg/kg but suppressed it at 25 mg/kg. In rats trained to discriminate the hallucinogen DOM or the entactogen MDMA, 25B-NBOMe fully substituted for both drugs at 0.5 mg/kg, but higher doses reduced drug-appropriate responding. 25C-NBOMe fully substituted for DOM but only partially for MDMA. 5-MeO-DALT fully substituted for DOM but not MDMA. 25I-NBOMe failed to fully substitute for either, likely due to its strong rate-depressant effects. The compounds appear attractive for hallucinogenic use but less so as MDMA substitutes, and their abuse potential matches that of scheduled compounds.
Behav Pharmacol
December 6, 2024
Daaniyal D. Munir, Ritu A. Shetty, Michael B. Gatch et al.
1 citation
Four novel synthetic hallucinogens structurally similar to 25X-NBOMe compounds—25B-NBOH, 25C-NBOH, 25E-NBOH, and 25I-NBOH—were tested in mice and rats. All four decreased spontaneous locomotor activity in mice, with effects similar in magnitude and potency to the hallucinogen DOM but less potent than 25X-NBOMe compounds. In rats trained to discriminate DOM, 25B-NBOH, 25C-NBOH, and 25E-NBOH fully substituted for DOM, indicating they produce similar psychoactive effects, while 25I-NBOH failed to fully substitute even at doses that suppressed responding. The findings suggest three of the four compounds are likely to be used recreationally as hallucinogens, whereas 25I-NBOH may have lower abuse liability.
Behav Pharmacol
July 1, 2026
Razeen J. Akbar, Amy D. Stringer, Sonita Wiah et al.
Psilocybin, a psychedelic compound, causes repetitive, stereotyped movements and reduces defensive reactions in planarian flatworms. These effects are mediated by the neurotransmitter serotonin (5-hydroxytryptamine). The findings suggest that psilocybin's behavioral actions in this simple animal model are linked to serotonergic signaling.